Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: Final survival analysis of the German ADEBAR phase III study.
Wolfgang Janni
Consultant or Advisory Role - AstraZeneca; Aventis; Pfizer
Research Funding - AstraZeneca; Aventis; Pfizer
Nadia Harbeck
No relevant relationships to disclose
Harald Leo Sommer
No relevant relationships to disclose
Brigitte Kathrin Rack
No relevant relationships to disclose
Doris Augustin
No relevant relationships to disclose
Wolfgang Simon
No relevant relationships to disclose
Julia Kathrin Jueckstock
No relevant relationships to disclose
Arthur Wischnik
No relevant relationships to disclose
Katja Annecke
No relevant relationships to disclose
Klaus Friese
No relevant relationships to disclose
Marion Kiechle
No relevant relationships to disclose